ABNOM
☆ In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
References
U laser Q-switched Nd:YAG hè cunnisciutu per trattà efficacemente nevus di Ota è cundizioni simili. Avemu realizatu un studiu per vede cumu bè un laser high-fluence 1064 nm Q-switched Nd:YAG hà travagliatu nantu à i spots monguli in spazii inusual, senza pruvucà a pelle per alluminà. Avemu studiatu 61 pazienti cun questi spots, esaminendu un totale di 70 lesioni. A mità di e ferite sò state trattate cù u laser, mentre chì l'altri ùn anu micca trattatu per paragunà. Avemu evaluatu i risultati cù una scala è un dispositivu chjamatu Mexameter® per misurà i livelli di melanina. I Pacienti sò stati seguiti per una media di 14 mesi in u gruppu di trattamentu è 18 mesi in u gruppu di osservazione. À a fine di u studiu, truvamu differenzi significativi in i punteggi di scala è i livelli di melanina trà i gruppi trattati è micca trattati, cù u gruppu trattatu laser chì mostra risultati megliu. U laser high-fluence Q-switched Nd:YAG , senza pruvucà un schiarimentu di a pelle, hè statu efficace è sicuru per trattà questi spots monguli inusual.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Avemu studiatu l'efficacezza è a sicurità di l'usu di un trattamentu laser specificu per ABNOM , è hà guardatu à quali fattori puderanu influenzà quantu funziona. Avemu guardatu à 110 pazienti chì anu avutu ABNOM è uttene trà dui è nove trattamenti laser. Avemu trovu chì u trattamentu hà travagliatu megliu u più longu hè statu fattu, ma micca cusì bè in i pazienti anziani. Hè ancu travagliatu megliu in i malati cù a pelle più ligera (tipu III) è i zoni affettati più chjuchi (menu di 10 cm2) . Avè melasma cù ABNOM hà fattu u trattamentu menu efficace. U culore o u numeru di zoni affettati ùn pareva micca fà a diferenza. Circa u 10% di i pazienti anu avutu punti più scuri dopu u trattamentu. I primi trattamenti multipli detti boni risultati. I pazienti anziani cù a pelle più scura è i punti più scuri sò più prubabile di ottene spots più scuri dopu u trattamentu. Per i malati cù ABNOM è melasma, hè megliu aduprà un laser di bassa energia per evità di peghju u melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Trattamentu
L'agenti di imbiancatura raramente aiutanu. A cuntrariu di melasma, ABNOM pò esse migliuratu cù trattamentu laser è lasciate per esse eliminati senza recurrence. U trattamentu laser pò esse realizatu da 10 à 20 volte per trattà ABNOM.
#QS1064 laser